Immunome (IMNM) to Release Earnings on Wednesday

Immunome (NASDAQ:IMNM) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.64) per share and revenue of $0.7850 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

Shares of IMNM stock opened at $21.86 on Wednesday. The stock’s fifty day simple moving average is $22.75 and its 200 day simple moving average is $17.95. Immunome has a one year low of $5.15 and a one year high of $27.65. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -9.03 and a beta of 2.12.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Leerink Partners set a $40.00 target price on Immunome in a research note on Monday, December 15th. Truist Financial began coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Craig Hallum raised their price target on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Stephens cut their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Finally, Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and a consensus target price of $33.45.

Insider Activity at Immunome

In related news, CEO Clay B. Siegall acquired 4,729 shares of the stock in a transaction dated Tuesday, December 30th. The stock was bought at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the transaction, the chief executive officer directly owned 665,254 shares of the company’s stock, valued at $14,070,122.10. The trade was a 0.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the transaction, the director directly owned 2,031,181 shares in the company, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have bought a total of 68,518 shares of company stock valued at $1,453,958 in the last 90 days. 7.69% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its position in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. increased its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the period. Primecap Management Co. CA increased its position in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. bought a new position in Immunome during the fourth quarter worth $30,710,000. Finally, State Street Corp lifted its holdings in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after buying an additional 1,064,027 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.